摘要
目的 研究慢性阻塞性肺疾病(COPD)合并非小细胞肺癌(NSCLC)患者血清miR-145-5p、miR-150-5p表达与病理特点和预后的关系。方法 选择温州医科大学丽水医院2016年12月至2020年12月收治的126例COPD合并NSCLC患者为研究组,同期收治的100例单纯COPD患者为对照组。采用qRT-PCR法检测并比较两组血清miR-145-5p、miR-150-5p相对表达水平,分析血清miR-145-5p、miR-150-5p表达与COPD合并NSCLC患者病理特点的关系。对COPD合并NSCLC患者术后进行3年随访,统计3年总体生存率,绘制Kaplan-Meier生存曲线,分析并比较血清miR-145-5p、miR-150-5p低/高表达组3年总体生存率。结果 与对照组进行比较时,研究组血清样本中miR-150-5p出现显著的表达上调(P<0.001),血清miR-145-5p的表达则显著降低(P<0.001)。与未发生淋巴结转移、TNM分期Ⅰ~Ⅱ期患者比较,发生淋巴结转移、TNM分期Ⅲ期患者中血清miR-145-5p低表达和miR-150-5p高表达患者的占比更高(P<0.05)。经过3年随访,126例NSCLC患者失访4例,总体生存率为36.07%(44/122)。在3年总体生存率指标上,miR-145-5p表达水平较高的组别(45.95%)显著优于表达水平较低的组别(31.76%)(P<0.05);与之相反,miR-150-5p高表达组的3年总体生存率(30.00%)显著低于低表达组(47.62%),且该差异经统计分析具有显著性(P<0.05)。结论 COPD合并NSCLC会导致血清miR-145-5p低表达、miR-150-5p高表达,且血清miR-145-5p、miR-150-5p表达与淋巴结转移、TNM分期升高及3年总体生存率降低相关,有望成为COPD合并NSCLC诊疗的新型分子标志物。
Objective To study the relationship between serum miR-145-5p and miR-150-5p expression and pathological characteristics and prognosis in patients with chronic obstructive pulmonary disease(COPD)combined with non-small cell lung cancer(NSCLC).Methods A total of 126 patients with COPD combined with NSCLC admitted to Lishui Hospital of Wenzhou Medical University from December 2016 to December 2020 were selected as the study group,and 100 patients with simple COPD admitted during the same period were selected as the control group.qRT-PCR was used to detect and compare the relative expression levels of serum miR-145-5p and miR-150-5p in the two groups.The relationship between serum miR-145-5p and miR-150-5p expression and pathological characteristics of patients with COPD combined with NSCLC was analyzed.Patients with COPD combined with NSCLC were followed up for 3 years after surgery.The 3-year overall survival rate was calculated,and the Kaplan-Meier survival curves were plotted to analyze and compare the overall survival rates at 3 years in the low/high expression groups of serum miR-145-5p and miR-150-5p.Results When compared with the control group,the expression of miR-150-5p was significantly upregulated in serum samples of the study group(P<0.001),while the expression of miR-145-5p was significantly downregulated in serum samples(P<0.001).Compared with patients without lymph node metastasis and TNM stageⅠⅡ,the proportion of patients with low expression of serum miR-145-5p and high expression of miR-150-5p was higher in patients with lymph node metastasis and TNM stageⅢ(P<0.05).After 3 years of follow-up,among 126 NSCLC patients,4 were lost to follow-up,with an overall survival rate of 36.07%(44/122).In terms of 3-year overall survival rate,the group with higher miR-145-5p expression levels(45.95%)was significantly better than the group with lower expression levels(31.76%)(P<0.05).On the contrary,the 3-year overall survival rate of the miR-150-5p high expression group(30.00%)was significantly lower than that of the low expression group(47.62%),and this difference was statistically significant(P<0.05).Conclusion The combination of COPD and NSCLC leads to low expression of serum miR-145-5p and high expression of miR-150-5p,and the expression of serum miR-145-5p and miR-150-5p is associated with lymph node metastasis,increased TNM stage and decreased 3-year overall survival rate,which is expected to become a new molecular biomarker for diagnosis and treatment of COPD combined with NSCLC.
作者
何婷
李雨玲
熊军芳
HE Ting;LI Yuling;XIONG Junfang(Department of Respiratory and Critical Care Medicine,Lishui Hospital of Wenzhou Medical University,The First Affiliated Hospital of Lishui University,Lishui People's Hospital,Lishui 323000,China)
出处
《空军军医大学学报》
2025年第10期1340-1345,共6页
Journal of Air Force Medical University
基金
浙江省医药卫生科技计划项目(2024KY588)。
关键词
慢性阻塞性肺疾病
非小细胞肺癌
血清
聚合酶链反应
病理学
肿瘤分期
预后
基因表达
chronic obstructive pulmonary disease
non-small cell lung cancer
serum
polymerase chain reaction
pathology
tumor staging
prognosis
gene expression
